Unknown

Dataset Information

0

Stable Protein Sialylation in Physcomitrella.


ABSTRACT: Recombinantly produced proteins are indispensable tools for medical applications. Since the majority of them are glycoproteins, their N-glycosylation profiles are major determinants for their activity, structural properties and safety. For therapeutical applications, a glycosylation pattern adapted to product and treatment requirements is advantageous. Physcomitrium patens (Physcomitrella, moss) is able to perform highly homogeneous complex-type N-glycosylation. Additionally, it has been glyco-engineered to eliminate plant-specific sugar residues by knock-out of the ?1,2-xylosyltransferase and ?1,3-fucosyltransferase genes (?xt/ft). Furthermore, Physcomitrella meets wide-ranging biopharmaceutical requirements such as GMP compliance, product safety, scalability and outstanding possibilities for precise genome engineering. However, all plants, in contrast to mammals, lack the capability to perform N-glycan sialylation. Since sialic acids are a common terminal modification on human N-glycans, the property to perform N-glycan sialylation is highly desired within the plant-based biopharmaceutical sector. In this study, we present the successful achievement of protein N-glycan sialylation in stably transformed Physcomitrella. The sialylation ability was achieved in a ?xt/ft moss line by stable expression of seven mammalian coding sequences combined with targeted organelle-specific localization of the encoded enzymes responsible for the generation of ?1,4-galactosylated acceptor N-glycans as well as the synthesis, activation, transport and transfer of sialic acid. Production of free (Neu5Ac) and activated (CMP-Neu5Ac) sialic acid was proven. The glycosidic anchor for the attachment of terminal sialic acid was generated by the introduction of a chimeric human ?1,4-galactosyltransferase gene under the simultaneous knock-out of the gene encoding the endogenous ?1,3-galactosyltransferase. Functional complex-type N-glycan sialylation was confirmed via mass spectrometric analysis of a stably co-expressed recombinant human protein.

SUBMITTER: Bohlender LL 

PROVIDER: S-EPMC7775405 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications


Recombinantly produced proteins are indispensable tools for medical applications. Since the majority of them are glycoproteins, their <i>N</i>-glycosylation profiles are major determinants for their activity, structural properties and safety. For therapeutical applications, a glycosylation pattern adapted to product and treatment requirements is advantageous. <i>Physcomitrium patens</i> (Physcomitrella, moss) is able to perform highly homogeneous complex-type <i>N</i>-glycosylation. Additionally  ...[more]

Similar Datasets

| S-EPMC3785464 | biostudies-literature
| S-EPMC5003249 | biostudies-literature
| S-EPMC5559433 | biostudies-literature
| PRJDB10184 | ENA
2022-06-19 | GSE205257 | GEO
| S-EPMC2871460 | biostudies-literature
| S-EPMC4384322 | biostudies-other
| PRJEB39976 | ENA
| S-EPMC3190705 | biostudies-literature
| S-EPMC5583724 | biostudies-literature